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Executive summary 
Key findings 
This paper presents new developments in relation to the use and misuse of 
benzodiazepines and highlights significant gaps in knowledge. In particular:  
 The increasing availability of unregulated benzodiazepines of unknown 
content and quality. 
 The use of excessive benzodiazepine-type drug doses by people  
self-medicating with prescribed and/or illicit benzodiazepine-type drugs. 
 The unclear role of benzodiazepine-type drugs in drug-related deaths (DRDs) 
and drug-associated mortality. 
 The real risks of short-term and long-term mental health and cognitive 
problems associated with routine and excessive benzodiazepine-type  
drug use. 
Background  
Benzodiazepine drugs are effective medicines when used appropriately for 
management and treatment of various conditions from anxiety to palliative care, as 
well as structured alcohol and substance withdrawal. However, they also have 
significant abuse and misuse potential, which increases the probability of related 
harms, including death. 
DRD is a major public health problem globally, with rates in Scotland higher than any 
other UK region and among the highest in Europe. Annual analysis of the National 
Drug-Related Death Database since 2009 has consistently shown opioids to be the 
most prominent group of substances involved in DRDs in Scotland. However, the 
vast majority of DRD cases also had a benzodiazepine present in post-mortem 
toxicology. Despite benzodiazepines continually featuring as a distinct component of 
the illicit drug market in Scotland and contributing to DRDs, there is little research on 
the role of benzodiazepines and benzodiazepine-type drugs in DRDs. Therefore, this 
has been identified as one of the priority areas for further investigation by the 
Scottish National Forum on Drug-Related Deaths. 
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Aim 
To investigate why benzodiazepine-type drugs are common in drug-related mortality, 
and what role they play in such deaths. 
Methods 
A systematic integrative literature review was undertaken. The literature search 
utilised Embase, Medline, Cochrane Systematic Reviews and University of York 
Centre for Reviews and Disseminations databases. As benzodiazepines dominated 
the anxiolytic and hypnotic market by 1970 it was considered an appropriate start 
date for the literature search. Therefore, databases were searched from 1970 to 
March 2015. 
As this study was examining the role of benzodiazepines in drug-related mortality, a 
reductionist approach to literature review was deliberately and intentionally avoided. 
Study inclusion criteria were therefore kept broad, covering major themes: 
benzodiazepine supply issues; pharmacokinetic and pharmacodynamic effects and 
interactions; adverse drug effects; polydrug use and interactions; toxicology; 
comorbidity; mortality; fatality and non-fatality information; and acute 
pharmacological overdose treatment. 
The non-benzodiazepines z-hypnotics were also included in the scope of this 
literature review, as they are known to be misused, share a similar mechanism of 
action and produce benzodiazepine-like effects. 
Also as part of this study, Senior Addictions Services Clinicians, Police Scotland 
National Drug Co-ordination Team, Forensic Toxicologists, Forensic Pathologists 
and Scottish Ambulance Service paramedics were interviewed as part of a wider 
scoping exercise. 
Results 
Supply and demand 
The widespread use and availability of benzodiazepine-type drugs from licit and  
illicit sources has made it harder to legislate for and restrict access. This is  
partially explained by internet availability, illicit manufacture and numerous 
benzodiazepine-type drugs being licensed in other countries (more than 30 
benzodiazepine-type drugs are available but only 16 are legislated for in the UK 
Misuse of Drug Regulations). 
The potential for diverting licit prescription supplies to the illicit market has reduced 
over the last 20 years as general practice and other prescribers have steadily 
reduced and restricted benzodiazepine-type drug prescribing. However, the 
increased availability of ‘street benzos’ and the emergence of benzodiazepine-type 
‘New’ or ‘Novel’ Psychoactive Substances (NPSs) have increased the complexity of 
substance use and related harms: self-medicating unwitting use of more potent 
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drugs; variability in drug potency and concentration; and easier access to larger 
quantities of supply. 
Although it is known that illicit supplies are associated with DRDs, there is a lack of 
studies assessing prescribed benzodiazepine-type drug use and ‘benzo-burden’ (the 
total benzodiazepine-type drug load prescribed per day expressed as diazepam 
equivalents) in relation to DRDs, and longitudinal studies of licit and illicit drugs 
present in DRDs. 
Pharmacokinetic considerations 
Benzodiazepine-type drugs share common metabolic pathways with opioids and 
other drugs commonly found in DRDs. When benzodiazepine-type drugs are used at 
normal licensed doses in conjunction with opioids such as methadone, studies fail to 
demonstrate significant changes in opioid concentrations. However, substance users 
routinely use supratherapeutic doses or ‘megadoses’ of benzodiazepine-type drugs 
which are 5–10 times the licensed doses, thus increasing their risks of significant 
interactions, in turn increasing opioid and other drug blood concentrations, and the 
risk of adverse effects. 
There are a lack of studies assessing drug metabolism and drug handling with high 
(unlicensed) doses of drugs of misuse and in overdose situations.  
Pharmacodynamic considerations 
Benzodiazepine-type drugs’ effects may be enhanced or diminished in the presence 
of other drugs, such as greater central nervous system depressive effects with 
alcohol or opioids. Buprenorphine is a partial opioid agonist with a ‘ceiling effect’ for 
respiratory depression which other opioids lack. However, this protective ceiling 
effect is diminished when buprenorphine is used in combination with 
benzodiazepines.  
Central nervous system depression also occurs from the synergistic effects of other 
drugs commonly found with prescribed and polydrug use: antidepressants, 
antiepileptics, antipsychotics, other opioids, etc. 
There is a lack of local and national studies assessing the differences between fatal 
and non-fatal ‘near-miss’ overdoses. It also may be appropriate to review and 
consider the role of buprenorphine in specific opioid substitution groups. 
Adverse effects 
Many of the benzodiazepine-type drugs’ adverse effects are commonly known: 
sedation, dependence, cognitive impairment, amnesia, etc. Cognitive impairment, 
however, may increase risk-taking behaviour and can reduce the effectiveness of 
psychosocial interventions and possibly even harm-reduction advice, which may play 
a role in DRDs. Less well known paradoxical and proarrhythmic effects may also 
play a significant role in DRDs.  
Paradoxical effects, also known as disinhibitory effects, such as increased anxiety, 
inappropriate behaviour, impulsiveness and aggression, are considered to be 
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uncommon. However between 1% and 20% of those prescribed normal doses  
of benzodiazepine-type drugs can be affected, with higher doses, the use of  
short-acting drugs and/or co-morbid mental health problems being associated with 
such adverse effects.  
At normal doses diazepam and other benzodiazepines have been shown to have 
arrhythmic effects on the heart, causing abnormal heart rhythms in susceptible 
individuals. These cardiac adverse effects are rarely reported with z-hypnotics. As 
substance users are more likely to use megadoses 5–10 times greater than a normal 
dose, these arrhythmic effects may contribute to DRDs. In addition, other drugs 
found in DRDs can cause or contribute to arrhythmias through QTc prolongation 
(e.g. methadone, tricyclic antidepressants) as well as comorbidities such as 
cardiovascular disease and electrolyte imbalance associated with liver disease. 
There is a lack of studies assessing the role of benzodiazepine-type drug effects in 
DRDs. Future work should consider: substance-users-reported differences in 
disinhibitory effects between drugs; how these adverse effects effect risk-taking 
behaviour; the differences in benzo-burden between suicide and non-suicide DRDs; 
differences in QTc interval for substance users prescribed and not prescribed 
benzodiazepines; potential dose-response relationships between benzodiazepines 
and QTc prolongation. 
Polydrug use and interactions 
The use of more than one psychoactive substance, known as polydrug use, is 
common among substance users. The use of such combinations increases the risk 
of drug–drug and drug–disease interactions, and further increases the risk of 
adverse drug effects. There is a lack of clarity around the impact of these potential 
and actual interactions, especially with the high doses used by substance users. 
There is a lack of studies assessing differences in different DRD populations 
(benzodiazepine implicated, present and not present); between genders; between 
fatal and non-fatal polydrug hospital admissions; and between different polydrug 
combinations and prescribed drug combinations.  
Toxicology 
Toxicology routinely screen for specific licensed benzodiazepines (including active 
metabolites) and zolpidem when investigating potential DRDs. In Scotland, zolpidem 
accounts for a small proportion of prescribed z-hypnotics, whereas zopiclone (not 
routinely screened for) accounts for the majority and has a slightly higher illicit street 
value than benzodiazepines. As benzodiazepine-type Novel Psychoactive 
Substance (NPS) use continues to grow it will further complicate routine screening. 
It is unclear what role drug blood concentrations play in DRDs, as there are 
significant overlaps in fatal and non-fatal intoxications. As benzodiazepine-type 
drugs are commonly found in combination with other drugs in DRDs, greater risks 
are more likely to be associated with polydrug combinations. 
Although it is known that benzodiazepine-type drugs are rarely found as single 
agents in DRDs, there is a lack of studies assessing benzo-burden and prescribing 
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patterns in ‘near-miss’ cases of accidental and intentional drug poisonings admitted 
to hospital. Owing to the widespread use of zopiclone and increased use of 
phenazepam and etizolam, it may be appropriate to consider their inclusion in 
routine screening. Due to the volume of toxicology data transferred to Police 
Scotland, it may be appropriate to consider single quarterly data transfers and a 
single point of contact between Police Scotland and Toxicology Services.  
Comorbidity 
In the general population it is well known that morbidity and multimorbidity increases 
with age. Multimorbidity is also associated with increased use of multiple prescribed 
medicines (polypharmacy) which in turn increases the risk of avoidable adverse drug 
effects. It is suspected that substance users in and out of treatment are at higher risk 
of developing multimorbidity and therefore will receive multiple medicines which may 
further complicate drug–drug and drug–disease interactions. Parallel to an ageing 
cohort of people who use drugs, the average age of DRDs has been increasing year 
on year and passed 40 for the first time in 2013. 
Conditions such as chronic obstructive pulmonary disease (COPD), liver disease 
and psychiatric comorbidities may exacerbate benzodiazepine-type drug effects. 
Substance users who are life-long smokers may be at greater risk of 
benzodiazepine-induced respiratory depression due to compromised respiratory 
function.  
There is a lack of studies assessing drug–disease interactions between 
benzodiazepine-type drugs and COPD, cardiovascular disease, liver disease and 
different mental health comorbidities. It may be appropriate to consider capturing 
common respiratory diseases: COPD, asthma and mixed asthma-COPD using 
separate coding.  
Mortality and prescribed benzodiazepine-type drugs 
There is conflicting evidence regarding benzodiazepine-type drugs being associated 
with increased mortality hazards for adults. However, a recent study did highlight that 
benzodiazepine-type drugs were associated with a greater risk of developing 
pneumonia and dying from pneumonia, which may play a significant role for  
immune-compromised substance users and those experiencing DRD ‘near-misses’ 
with accidental overdoses. 
There is a lack of studies assessing the sequelae of non-fatal benzodiazepine-type 
drug overdoses in people who may subsequently die of pneumonia.  
Acute pharmacological treatment of benzodiazepine-type drug 
overdose 
The greater use of antidotes may have a positive impact on reducing DRDs, but 
there are limitations to their use. Flumazenil is a short-acting benzodiazepine 
antagonist widely available in the UK. However, it is not licensed for use in overdose, 
as its use can be hazardous in mixed overdoses involving tricyclic antidepressants or 
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in benzodiazepine-dependent patients, and requires the correction of respiratory, 
cardiac and metabolic conditions before administration. 
Naloxone, a short-acting opioid antagonist, has been used with mixed success to 
reverse benzodiazepine and z-hypnotic effects. Interestingly, the studies which 
demonstrated a lack of effect used benzodiazepine doses at half to less than a tenth 
of those seen in overdoses and may not have given enough time for patients to 
respond. Although there are differing theories explaining why naloxone can be 
effective in benzodiazepine overdoses, further research is required to confirm or 
refute these hypotheses. However, the majority of benzodiazepine-related DRDs are 
commonly associated with polydrug use, often involving opioids, which presents 
barriers to undertaking such research.  
Conclusion 
The role of benzodiazepine-type drugs in DRDs is complicated by numerous factors, 
including the use of supratherapeutic megadoses and the lack of information about 
the metabolic and physical effects of such doses; the increasing use of 
benzodiazepine-type NPSs; polydrug use and polypharmacy further complicating 
adverse drug effects; low and high drug blood concentrations being present in 
DRDs; and benzodiazepine-type drugs being associated with increased mortality 
when used at routine doses.  
However, in assessing the risks posed by benzodiazepine-type drugs, one must 
consider the risks of the alternatives such as NPS and other substances. Therefore, 
a better understanding of benzodiazepine-type drug use may enable the 
development of appropriate strategies to reduce and minimise drug-related harms, 
and to replicate previous achievements associated with the withdrawal of 
temazepam capsules.  
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Introduction 
Drug-related death (DRD) is a major contributor to premature mortality 
internationally, with rates in Scotland higher than any other UK region and among 
the highest in Europe.1 In the USA an epidemic of deaths caused by prescription 
opioids is of national concern.2 As part of its response, the Scottish National Forum 
on Drug-Related Deaths (NFDRD) established a National Drug-Related Death 
Database (NDRDD) in 2009. This was designed to replace a series of single 
research studies which had investigated those deaths attributed to methadone and 
later deaths in drug users from all causes.3,4 The new database was designed to 
provide detailed accounts of the characteristics of the individuals involved in  
drug-related mortality and the circumstances surrounding their deaths, and to 
establish a longitudinal resource to measure and observe trends in causes of DRDs. 
Analysis of the database provides important evidence and intelligence for policy and 
practice to inform future prevention and treatment strategies.  
Annual analysis of the NDRDD since 2009 has consistently shown opioid use to be 
the most prominent substance involved in DRDs in Scotland.5 Despite decreasing 
heroin presence in DRD toxicology since 2009, opioids continued to be implicated in 
a high proportion of deaths, as defined by the reporting pathologist. However, the 
vast majority of DRD cases featured individuals who had used multiple drugs prior to 
death, including, in many cases, diazepam. Despite continually featuring as a 
distinctive component of the illicit drug market in Scotland,a,b;6–8 there is little research 
on the role of benzodiazepines (of which diazepam is one) in DRDs and their 
influence in terms of toxicology and decision-making or risk perception. Indeed 
benzodiazepines were one of four key topics (alongside mental health, 
multimorbidity and methadone overdoses) highlighted by the NFDRD to be 
prioritised for research in terms of their role in drug deaths.9 
This research will therefore address one of the priority areas identified by the 
NFDRD, that of benzodiazepines, and be used to inform future policy and practice in 
this area.  
  
                                                          
a Stewart I, Tough A. ‘The examination of illicit blue diazepam tablets’. Abertay University 
and Robert Gordon University; July 2014. Unpublished report. 
b Scottish Drugs Forum. ‘National Volunteers Forum. Street benzodiazepines: Blues. 
Qualitative study on availability and effects of illicit blue diazepam’. 2015. Unpublished 
report. 
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Background 
Benzodiazepines are among the most widely prescribed psychotropic drugs in the 
world. Over the last 30 years Scotland has had a strong relationship with the misuse 
of benzodiazepines, from temazepam, diazepam, and triazolamc in the  
mid-1980s7,10,11 to the ‘New’ or ‘Novel’ Psychoactive Substances (NPSs) such as 
etizolam and phenazepam in the 2010s.5,12 This is within an environment where 
benzodiazepine prescribing in primary care has steadily reduced over the last  
20 years13 (see Appendix 1). In part these reductions are due to concerns about 
benzodiazepine dependence and inappropriate prescribing,14,15 and have been 
achieved by general practitioners and prescribing support teams working to review 
and reduce benzodiazepine and z-hypnotic prescribing where appropriate.16,17 
Increasingly, the illicit market supply of benzodiazepines has replaced and 
superseded the availability of benzodiazepines on prescription. However, the vast 
majority of DRDs are associated with polydrug use, with benzodiazepines continuing 
to play a significant role in Scotland,5 Europe,18,19 the USA20–23 and Australia.24,25 
There are more than 30 different benzodiazepine drugs which share a common 
mechanism of action producing a range of similar effects. These can be divided into 
different groups based on their chemical structure and pharmacokinetic profile.26,27 
Shorter-acting drugs such as temazepam are generally used as hypnotics at night, 
whereas longer-acting drugs such as diazepam are usually used as anxiolytics and 
are considered to be less addictive. Benzodiazepines enhance the activity of 
gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter, at GABAA 
receptors which also have multiple sites for barbiturates, alcohol and z-hypnotic 
activity.27,28 They can be administered by a variety of routes: oral, injection, buccally, 
intra-nasally and rectally,29 and demonstrate varying degrees of efficacy when used 
to treat anxiety, insomnia, epilepsy, muscle spasms, dystonia, management of 
perioperative procedures, palliation, and alcohol and substance withdrawal.29–34 
Substance users may also seek illicit benzodiazepines to reduce and self-manage 
anxiety, insomnia and withdrawal symptoms or to improve their coping skills.34 
As a proportion of anxiolytic and hypnotic prescribed defined daily doses (DDDs),d 
temazepam use has dropped significantly, while zopiclone use has increased 
significantly, since the early 1990s (Appendix 1). In part this is due to prescribers 
being more aware of temazepam misuse10 and z-hypnotics being marketed and 
perceived as a safer alternative, although they lack any clear therapeutic advantages 
over benzodiazepines.36,37 However in September 2012 the cost of temazepam in 
the UK increased more than tenfold, which may have encouraged further reductions 
                                                          
c Triazolam was withdrawn from the UK market in 1991 and is currently available as a 
prescribable medicine in some countries, such as New Zealand. 
d World Health Organization DDDs are defined as ‘the assumed average maintenance dose 
per day for a drug used for its main indication in adults’. They do not necessarily reflect the 
recommended or prescribed daily dose but provide a standardised method to compare 
prescribing volumes between organisations.35 
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as, anecdotally, prescribers reviewed temazepam use and considered prescribing 
zopiclone as a more cost-efficient alternative. 
Diazepam prescribing has increased (Appendix 1) due to a combination of factors: it 
is the drug of choice for benzodiazepine and/or z-hypnotic withdrawal;29,38,39 it has a 
range of tablet strengths allowing for greater flexibility in prescribing and allowing 
lower doses to be prescribed, e.g. 1mge and 2mg;29 and it has been the most  
cost-effective benzodiazepine for a number of years40 (see Table 1). In general, the 
total benzodiazepine-type drug prescribing has reduced since the early 1990s 
(Appendix 1). 
 
                                                          
e Small diazepam doses can be given by halving 2mg tablets or using diazepam 2mg/5ml 
oral solution.  
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Table 1 Benzodiazepine equivalent doses, pharmacokinetics and prescribing information 
Drug Approximate 
equivalent dose 
(mg)d 
Time to peak for 
oral 
administration (h)e 
Half-life (h) [active 
metabolite (h)]f 
Preparation Cost for 28 dosesg 
Diazepam 10 1–1.5 20–100 [36–200] Tablets £1.23 to £5.35 
Clonazepama 0.5 1–4 20–60 Tablets £1.56* 
Lorazepam 1 2 10–20 Tablets £2.49 
Alprazolamb 0.5 1–2 9–20 Tablets £2.96* 
Zopiclone 15 1.5–2 4–6 Tablets £3.20 to £6.24 
Zolpidem 20 0.5–3 2–6 Tablets £3.42 to £7.12 
Nitrazepam 10 2 15–38 Tablets £5.02 
Clobazama 20 0.25–4 36 [79] Tablets £5.98* 
Oxazepam 30 1–5 4–15 Tablets £6.48 to £9.57 
Chlordiazepoxide 30 1–2 5–30 [36–200] Capsules £9.79 
Temazepam 20 1 8–22 Tablets £13.70 to £27.36 
Zaleplon 20 1 1 Capsules £15.04* 
Loprazolam 1 4 6–12 Tablets £18.00 
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Drug Approximate 
equivalent dose 
(mg)d 
Time to peak for 
oral 
administration (h)e 
Half-life (h) [active 
metabolite (h)]f 
Preparation Cost for 28 dosesg 
Lormetazepam 1–2 1.5 10–12 Tablets £31.04 
Chlordiazepoxide 30 As above As above Tablets £41.58 
Midazolam 10 1 2.2 Tablets Discontinued UK 
Phenazepamc 
(fenazepam) 
1 1.5–4 15–60 n/a  
Etizolamc 1 1–2 6 n/a  
a. Reserved for treatment of epilepsy 
b. Blacklisted non-NHS; only available on private prescription. 
c. NPSs 
d. Approximate oral equivalents – the drug half-lives vary significantly and individual patient response will vary, therefore caution and clinical 
judgement is required when switching between drugs. 
e. Time to peak will vary with stomach contents, gastric motility, preparation used (liquid or tablet) and route of administration (intravenous, 
intramuscular, rectal etc.)41 
f. Half-life varies with patient’s age, comorbidities and/or size of drug dose: older adults slower clearance, reduced in hepatic impairment41 and 
may increase in overdose situations. 
g. Drug costs from the Scottish Drug Tariff Part 7 April 201540 and BNF 6929 (BNF drug costs are updated annually for some drugs). Some drug 
preparations have a range of costs depending on which tablet preparation used, e.g. oxazepam as 3x10mg or 2x15mg for 30mg dose. 
Source: drug equivalent, time to peak and half-life adapted from BNF 69;29 Ashton Manual;38 UK Drug Misuse and Dependence Guidelines;33 
electronic Medicines Compendium;42 Phenazepam review.43 
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Substance users report using supratherapeutic or ‘mega dose’ oral and/or 
intravenous temazepam and/or diazepam to boost opiate effects; intensifying 
intoxication and pleasure,44–46 with median doses ranging from 40mg to 150mg.10,44 
The withdrawal of temazepam liquid capsules in the 1990s altered benzodiazepine 
injecting habits, with consumers in Scotland being more likely to take oral 
temazepam or diazepam.6,7 For some, however, drug-related risks increased 
through injecting the contents of gel-filled temazepam capsules or wider 
experimentation and/or multiple drug use.6 In Australia, by contrast, some changed 
to injecting Unisom (an antihistamine diphenhydramine) liquid capsules.45 The 
withdrawal of temazepam gel capsules was associated with a reduction in 
benzodiazepine-associated DRDs in the UK.47 
It is hard to estimate the prevalence of benzodiazepine use and misuse among 
people in opiate substitution treatment. Across Europe, 11% of those entering 
treatment report benzodiazepine use as a secondary drug problem, with some 
countries having higher reported use on entering treatment – 30% to 50%.48 
However, it should be noted that secondary drugs, including benzodiazepines, are 
often under-reported.48 An audit of co-prescribing in the NHS Greater Glasgow and 
Clyde Health Board area in 2013 indicated that approximately 25% of people 
receiving treatment for opiate dependence also received one or more prescriptionsf 
for benzodiazepine-type drugs in a 3-month period.49  
As with benzodiazepines, there have also been reports of z-hypnotic misuse and 
dependence, with some users experiencing euphoria.50–54 Zopiclone and zolpidem 
users have reported taking average daily doses of 105mg (range 60mg to 380mg) 
and 298mg (range 10mg to 1120mg), respectively, with the occasional case reports 
of injecting or snorting z-hypnotics.51,53–55 
  
                                                          
f Some of these will be single prescriptions for short-term use: benzodiazepine for alcohol 
withdrawal, anxiety and/or insomnia treatment. Other longer-term prescriptions may be for 
managed benzodiazepine reductions in line with current guidance.29  
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Methods 
An extensive systematic integrative literature review was undertaken using the 
Embase, Medline, Cochrane Systematic Reviews and University of York Centre for 
Reviews and Disseminations databases. As chlordiazepoxide and diazepam were 
the most commonly prescribed anxiolytics and nitrazepam’s share of the hypnotic 
market had grown significantly by 1968, 1970 was considered an appropriate start 
date for the literature search.56 Therefore, databases were searched from 1970 to 
March 2015.  
Search terms included: known benzodiazepines,26,29,38 benzodiazepines, anxiolytics, 
hypnotics, mortality, death, drug-related mortality poisoning, overdose, etc. Studies 
were limited to English-language publications involving humans. As benzodiazepines 
are used to treat numerous conditions, exclusion criteria included: child, newborn, 
infant, sclerosis, seizures, epilepsy, alcohol withdrawal, palliative care, artificial 
ventilation, anaesthetic and perioperative use. Antipsychotics, barbiturates, 
gabapentin and pregabalin which can be used to reduce agitation and anxiety were 
also excluded.29 These terms were systematically used in combination to conduct 
the searches (see Appendix 2 for search terms and exclusion terms used). Grey 
literature was identified from discussion with specialists, and reference lists, 
bibliographies, guidelines and internet resources were also searched where 
appropriate. 
As this study was examining the role of benzodiazepines in drug-related mortality, a 
reductionist approach to literature review was deliberately and intentionally avoided. 
Therefore, study inclusion criteria were kept broad, covering major themes: 
benzodiazepine supply issues; pharmacokinetic and pharmacodynamic effects and 
interactions; adverse drug effects; polydrug use and interactions; toxicology; 
comorbidity; mortality; fatality and non-fatality information; and acute 
pharmacological overdose treatment. 
The non-benzodiazepines, z-hypnotics, were also included in this extensive 
systematic integrative literature review, as they are known to be misused, share a 
similar mechanism of action to benzodiazepines and produce benzodiazepine-like 
effects.10,50  
As part of this study, a scoping exercise was also undertaken in which healthcare 
and non-healthcare workers involved in treating and managing drug-related issues 
were interviewed. These included Senior Addictions Services clinicians, the Police 
Scotland National Drug Co-ordination Team, forensic toxicologists, forensic 
pathologists and Scottish Ambulance Service paramedics. 
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Figure 1 Search results 
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through searching of databases 
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Results 
Supply and demand 
The widespread use and availability of different benzodiazepine drugs across the 
world has enabled and influences the licit and illicit sources of benzodiazepines, 
although recent evidence suggests that illegal ‘street benzo’ manufacturing is 
actively supplying the market with imitation benzodiazepine-type products of varying 
strengths and potency.9 In Scotland in 2013/14 there were 2.1 million anxiolytic and 
hypnotic prescriptions dispensed to 7% (367,597) of the Scottish population, who 
received one or more prescriptions; 70% of these were for benzodiazepines and 
28% for z-hypnotics.13 The majority of benzodiazepine-type drugs are prescribed by 
general practitioners as the initiating prescriber or on the advice of specialist services 
such as general medicine, psychiatry, and addiction and alcohol services, where 
approximately 25% of those prescribed opiate substitution therapy were also 
prescribed a benzodiazepine and/or z-hypnotic for conditions previously outlined.49 
Anecdotally and historically, small quantities of benzodiazepines, z-hypnotics and 
methadone have been diverted by patients.51,57–59 However, the wider use of 
instalment dispensing and supervised consumption, attempts to better control and 
minimise the risk of diversion, as well as more general practices reviewing and 
reducing prescribing in recent years have impacted on diversion, with service users 
themselves now acknowledging the impact of such interventions: ‘So people buy as 
much as they have money for’.10,16,17,33 In addition, the electronic transfer of 
prescriptions in Scotland has reduced the risk of them being forged or amended by 
people.g  
The emergence of NPSs has increased the complexity of substance use and related 
harm. Benzodiazepine-type NPSs are a complex mix of licit and illicit substances for 
which variations in legislation and licensing between different countries affect the 
legality of supply within the UK.61 Internet and ‘street’ sources are associated with a 
wide variety of benzodiazepines being available. Recent analysis of illicit ‘blue’ 
diazepamh demonstrates that there are wide variations in their diazepam content 
from zero to 48mg, with some tablets containing benzodiazepine-type NPSs such as 
phenazepam or etizolami which are significantly more potent (see Table 1).9 
                                                          
g Since 2008, prescriptions issued and printed in primary care have an electronic copy, 
stored as a secure electronic message, and a paper copy with a unique identifier bar code. 
When the paper copy of the prescription is presented to the pharmacy it is scanned; the 
electronic version is checked and can prepopulate the dispensing information. As the 
prescriptions are not handwritten it reduces the potential for forged prescriptions.60 
h Diazepam tablets made to resemble legitimate diazepam 10mg tablets which are blue. The 
analysis was carried out as partnership working between Abertay University, The Robert 
Gordon University and the Specialist Crime Division of Police Scotland. 
i Phenazepam is a benzodiazepine developed in the Soviet Union in the 1970s and widely 
available in the Russian Federation.43,62 Etizolam is a benzodiazepine developed in Japan in 
the 1970s63 and available in Japan, India and Italy.61 
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Substance users report ‘blues’ and ‘yellows’j supplies coming as loose tablets, strip 
packs and boxes like genuine tablets from legitimate pharmaceutical production lines 
with discount purchasing incentives, e.g. £1 per tablet or 28 tablets for £20–£25. 
Interestingly, however, zimmo’s (branded zopiclone) has a slightly higher street 
value at £1–£2 per tablet.10,61 
Indications from both seizure data and anecdotal feedback from peer networks 
suggest that drug users are taking phenazepam unknowingly and are therefore 
unaware of the level of risk.62 Users also report that these drugs have varying effects 
from none or little effect to unexpectedly being sedated and ‘being out of it for a 
couple of days’.10 Historically, there have also been anecdotal reports of blue 
warfarin 3mg tablets being sold as ‘blue’ diazepam. However, benzodiazepines may 
also be accidentally consumed as adulterants in other illicit products such as heroin 
mixed with alprazolam; one of the more potent and reportedly more toxic 
benzodiazepines.64–66 
Over the years there have been changes in drugs used, with a fall in temazepam 
and a subsequent rise and fall in diazepam use, a rise in z-hypnotic use and the 
recent emergence of benzodiazepine-type NPSs such as phenazepam and 
etizolam.5,12,51,67 As already acknowledged, some of this change may have been 
driven by the withdrawal of temazepam capsules and changes in drug use,6,7,36,45 as 
well as general reductions in availability as general practices restrict prescribing.16,17 
However, in assessing the risks posed by benzodiazepine-type drugs, one must 
consider the risk of alternatives. When New York State altered its benzodiazepine 
prescribing regulations in 1989, benzodiazepine-related overdoses in New York City 
significantly declined, whereas overdoses of other sedative-hypnotics significantly 
increased, with the legislation achieving no overall change in the number of sedative 
overdoses.68 In the current internet age it is plausible to assume that easier access 
via internet supplies and NPS benzodiazepines would maintain availability, possibly 
even leading to increased use.10 Although New York City has seen changes in drugs 
implicated in deaths, it is unclear what impact general practice benzodiazepine 
prescribing restrictions have had on use and misuse across the UK. 
As already acknowledged, self-medicating with benzodiazepine-type drugs is 
common to treat withdrawal symptoms. However, it is unclear what impact current 
reductions in methadone prescribing69,70 are having on benzodiazepine-type drug 
use, especially as average methadone doses in England and Wales are estimated to 
be 46mg per day70 which is significantly lower than the 60mg to 120mg per day 
maintenance doses advised in current guidance.33 
All NHS patients in Scotland have a Community Health Index (CHI) number that acts 
as a unique identifier and provides information on gender and date of birth.71 The 
national Prescribing Information System (PIS) contains information on all NHS 
prescriptions dispensed in the community, of which over 95% include the patient’s 
CHI number.72 It is therefore possible to link PIS benzodiazepine and z-hypnotic 
prescribing data with individual patient records in the NDRDD, so future analysis 
should consider analysing prescribing patterns within the NDRDD cohort. 
                                                          
j ‘Yellows’ 5mg diazepam tablets. 
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Policy consideration 
The majority of benzodiazepines and z-hypnotics which are currently licensed in 
the UK are ‘controlled drugs’ under the Misuse of Drugs Act 1971. They are listed 
in Schedule 4 (Part 1), except for midazolam and temazepam which are in 
Schedule 3 and subject to special prescription requirements and safe custody 
requirements.29  
Addition of all known benzodiazepine-type NPSs to Schedule 4 (Part 1) may 
appear to be a solution to control drug supplies. However, this may in fact increase 
risks to substance users as ‘street’ and internet suppliers may promote and sell 
other drugs which have greater risks and cause more harm. 
 
Clinical practice research considerations 
 General practices are reducing benzodiazepine and z-hypnotic prescribing. 
What impact has reduced prescribing had on drug availability and use of 
alternative benzodiazepine-type drugs? 
 Analysis and use of routine data from the NDRDD, PIS and other datasets 
to inform practice and trends by answering the following: 
o What is the prescribed benzo-burdenk and prescribing patterns prior to 
DRD? 
o How does DRD cases benzo-burden and prescribing patterns compare 
with ‘near miss’ cases of intentional and accidental drug poisonings 
admitted to hospital? 
 The proportion of people with DRDs and prescribed diazepam appears to 
be increasing year on year: 13% (2010), 16% (2011), 17% (2012), 21% 
(2013).5 Is there an underlying trend or change in prescribed benzo-burden 
over the years, i.e. people prescribed lower benzodiazepine-type drug 
doses and/or lower doses of opiate substitute? 
 
 
  
                                                          
k Benzo-burden: the total benzodiazepine-type drug load, including all benzodiazepine and 
z-hypnotics prescribed per day, expressed as diazepam equivalents. 
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Toxicology and pathology research consideration 
 Analysis and use of routine data from the NDRDD, PIS and other datasets 
to inform practice and trends by answering the following: Does the 
prescribed benzo-burden and benzodiazepine-type drugs found in DRD 
cases correlate with toxicology findings? 
Pharmacokinetic considerations 
Benzodiazepines are extensively metabolised in the liver by phase I and phase II 
metabolic processes. Phase I involves cytochrome P450 enzymes, predominantly 
CYP 3A4, with benzodiazepines competing for the same metabolic pathway as other 
psychoactive drugs, such as buprenorphine, methadone, z-hypnotics, 
antidepressants and antipsychotics, at normal doses, along with chronic 
consumption and alcoholl (Table 2).39,43,73 Although buprenorphine is a CYP 3A4 
substrate, there is a currently a lack of evidence supporting a pharmacokinetic 
interaction with benzodiazepines at normal doses.46,74–76 Studies using routine 
benzodiazepine (≤40mg diazepam equivalent) and methadone doses (mean dose 
50mg to 69mg) failed to demonstrate an increase in methadone concentrations, but 
did demonstrate greater intoxication, pupil constriction, euphoria and performance 
impairment.46  
However, when substance users take supratherapeutic or megadoses of 
benzodiazepines, such as diazepam, which are often 3–5 times the maximum 
licensed dose,10 or when these are taken as a deliberate overdose, there will 
potentially be greater competition for the CYP 3A4 pathway. This will reduce 
clearance and increase the risk of drug accumulation of one or more drugs (Table 2), 
potentially increasing toxicity and resulting in further problems, such as increasing 
blood methadone concentration.39,75 As z-hypnotics share this same CYP 3A4 
pathway and are known to be taken at 6–10 times normal dose, this will also 
increase the risk of interactions.51,53 Gender also plays a role in zolpidem clearance, 
as females achieve up to 50% higher blood concentrations than males, putting them 
at greater risk of overdose.77 In contrast, zolpidem clearance in males is reduced 
with lower blood testosterone concentrations.78 
Phase II involves glucuronidation with benzodiazepines being predominantly 
metabolised by uridine diphosphate glucuronosyltransferase (UGT) 2B7 enzyme. 
Unlike other benzodiazepines which undergo extensive metabolism in phase I, 
lorazepam, oxazepam and temazepam are substrates for UGT 2B7 and are 
predominantly metabolised by glucuronidation prior to excretion (see Table 2). 
However, the metabolism of these drugs is complicated by the fact that some 
benzodiazepines, such as diazepam, inhibit glucuronidation. In phase I metabolism 
at normal therapeutic doses, diazepam is transformed to its active metabolites, 
                                                          
l Ethanol is predominantly metabolised by alcohol dehydrogenase. In alcohol misusers  
CYP 2E1 plays a significant role in metabolising ethanol to acetaldehyde, which is then 
metabolised by aldehyde dehydrogenase. Chronic alcohol consumption induces CYP 3A4, 
CYP 1A2 and CYP 2B6.40 
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oxazepam and temazepam, which are UGT 2B7 substrates. However, the parent 
drug diazepam can inhibit UGT 2B7 activity, which will result in active metabolite 
(oxazepam and temazepam) accumulation and increased drug effects, especially 
when megadoses are taken by substance users or in overdose.79 As morphine is 
also a UGT 2B7 substrate, diazepam will inhibit its metabolism and diazepam’s 
active metabolites (oxazepam and temazepam) will compete with morphine for UGT 
2B7 glucuronidation, increasing the blood concentrations of one or more of these 
drugs.  
It would be expected that the use of megadoses by substance users will increase the 
potential for adverse drug effects due to higher blood concentrations. However, 
evidence is lacking for a clear linear relationship between benzodiazepine blood 
concentrations and DRD, as low to very high benzodiazepine concentrations have 
been implicated in DRDs.43,80,81 As with other drugs, it is suspected that there will be 
significant variations in benzodiazepine-type drug tolerance and susceptibility 
between individuals due to: variations in previous drug use; drug handling and 
clearance, possibly affected by phase I and II metabolism such as enzyme 
saturation; inhibition and/or competition due to benzodiazepine-type drugs and their 
metabolites; comorbidities and drug–drug interactions with prescribed drugs and 
polydrug use.82 
Toxicology and practice research consideration 
 Does the metabolism of benzodiazepine-type drugs change when very high 
doses (unlicensed doses) are used and does this affect the metabolism of 
other drugs commonly found in DRDs? 
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Table 2 Interactions of psychotropic drugs with cytochrome P450 and glucuronidation  
Enzyme 
systems 
Benzodiazepines 
and z-hypnotics 
Opioids Tricyclic 
antidepressants 
SSRIs Other ADMs Alcohol Antipsychotics 
CYP 2C19 Diazepam (S) ++ 
Nordiazepam (S) 
++ 
?Methadone 
(S)+ 
Imipramine (S) + 
Trimipramine (S) 
+ 
 
Citalopram (S) 
++ 
Escitalopram 
(S) +++ 
Escitalopram (I) 
+ 
Fluoxetine (S) + 
Sertraline (S) + 
   
CYP 3A4 Alprazolam (S) 
+++ 
Clonazepam (S) 
+++ 
Diazepam (S) ++ 
Etizolam (S) +++ 
?Flurazepam (S) 
+++ 
Midazolam (S) 
+++ 
Nitrazepam (S) 
+++ 
Buprenorphine 
(S) ++ 
Methadone (S) 
+++ 
Amitrptyline (S) 
++ 
Clomipramine 
(S) ++ 
Dosulepin (S) 
+++ 
Trimipramine (S) 
+ 
Citalopram (S) 
++ 
Fluoxetine (S) + 
Fluoxetine (I) 
+++ 
Fluvoxamine (I) 
++ 
Paroxetine (I) 
+++ 
Sertraline (S) + 
Trazodone (S) 
+++ 
Venlafaxine 
(S) ++ 
Intoxicated 
(S) ++ 
 
Aripiprazole (S) 
+++ 
Chlorproimazine 
(S) ++ 
Clozapine (S) + 
Quetiapine (S) 
+++ 
Risperidone (S) + 
Sertindole (S) 
+++ 
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Enzyme 
systems 
Benzodiazepines 
and z-hypnotics 
Opioids Tricyclic 
antidepressants 
SSRIs Other ADMs Alcohol Antipsychotics 
?Phenazepam (S) 
Triazolam (S) +++ 
Zaleplon (S) +++ 
Zolpidem (S) +++ 
Zopiclone (S) +++ 
Glucu  
UGT 2B7 
Clonazepam (I) 
Diazepam (I) 
Flunitrazepam (I) 
Lorazepam (S & I) 
Nitrazepam (I) 
Oxazepam (S & I)  
Temazepam (S) 
Buprenorphine 
(S) 
Morphine (S) 
 
Amitriptyline (I) 
Clomipramine (I) 
 
   Chlorpromazine 
(I) 
ADMs: antidepressant medicines; CYP: cytochrome P450; Glucu: glucuronidation; I: inhibitor. S: substrate; SSRIs: selective serotonin re-
uptake inhibitors. 
+ low (clinically insignificant at normal doses); ++ medium (clinical significance unclear/unknown at normal doses); +++ high (clinically 
significant at normal doses); ?: probably metabolised by enzyme.  
Amended from Maudsley, phenazepam, etizolam and glucuronidation studies.39,43,73,79 
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Pharmacodynamic consideration 
As outlined above, changes in drug handling due to dose taken, reduced clearance, 
accumulation, etc., will affect drug pharmacodynamics – the action of drugs on the 
physiology or pathology of the body. The concomitant use of another drug or multiple 
drugs may enhance or diminish pharmacodynamic effects, for example alcohol 
enhancing the central nervous system (CNS), depressive effects of benzodiazepines 
and vice versa or increasing paradoxical effects.83 However, as well as being a 
central nervous system depressant, alcohol acts at the GABAA receptor complex and 
can affect benzodiazepine metabolism as outlined above.  
Buprenorphine is a partial opioid agonist with a ‘ceiling effect’ for respiratory 
depression, which potentially offers safety advantages over other opioids, and is 
commonly used in some countries as an opiate substitute.74 Interestingly, although 
pharmacokinetic interactions between benzodiazepine-type drugs and 
buprenorphine are currently thought not to occur when normal doses are used, there 
are additive and/or synergistic interactions increasing CNS depressive effects, 
reducing and inhibiting the protective respiratory depression ‘ceiling effect’.46,74–76 
However, as noted above, substance user benzodiazepine megadoses are 
commonly 5 to 6 times higher than the maximum licensed doses, with the use of 
such doses significantly increasing the potential for greater CNS depression. The 
potential use of megadoses is of concern as DRDs have occurred when 
buprenorphine and benzodiazepine drug concentrations have been within the normal 
therapeutic range.84–87 
Studies which indicate that buprenorphine is safer than methadone rarely consider or 
report combination benzodiazepine use or the differences between cohorts 
prescribed methadone or buprenorphine.70,88,89 One study did consider 
benzodiazepine prescription use, although it did not consider benzo-burden or total 
daily dose used. It reported greater accident and emergency use and a greater risk 
to females who were co-prescribed buprenorphine and benzodiazepines over a 12-
month period.90 Unfortunately, the study sample was too small to assess for 
overdose death rates, substance users who were considered to have an atypical 
response to benzodiazepines were excluded and users attended an intensive 
outpatient programme. All of which may have excluded more chaotic individuals with 
greater drug-related risks/behaviours that may increase their risk of DRD. Another 
study acknowledged that the difference between unsupervised methadone (up to 
four doses dispensed weekly, unsupervised) and supervised buprenorphine (rarely 
prescribed unsupervised) consumption may have had a role in contributing to less 
drug diversion, although they did not think this influenced the overall benefits seen 
with buprenorphine.88  
At first glance the French experience with buprenorphine appears compelling, with 
an 80% reduction in DRDs between 1995 and 1999, after the loosening of 
restrictions on buprenorphine prescribing in 1996.91 The changes in legislation 
allowed all registered medical doctors to prescribe buprenorphine without a 
requirement for supplementary educational programmes or special licensing, and 
community pharmacies to dispense buprenorphine, resulting in the wider use of 
opiate substitution treatment within general practice, with buprenorphine accounting 
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for 80% of that treatment. At the same time buprenorphine legislation changed in 
France, needle exchange programmes were introduced and there was a possible 
change in attitude towards intravenous drug users by health care providers.91 In 
contrast, methadone prescribing remains restricted to doctors working in state-
licensed substance abuse clinics or hospitals where prescriptions are initially 
dispensed only on site.91 The observed differences in DRD rates between patients 
treated with buprenorphine and methadone89 may be due to subtle differences 
between these populations, general practice and specialist care, which may be 
associated with variations in lifestyle and risk-taking behaviours. Those under 
specialist care receiving methadone may have more chaotic lives, greater risk-taking 
behaviours and/or greater polydrug use. 
Despite the apparent success of the French buprenorphine policy, it is concerning 
that 45% of people in opiate substitution treatment in France currently use 
benzodiazepines,48 which would be expected to increase the risk of DRD. Moreover, 
there are still multiple confounding factors which may have played a role in the 
observed DRD reductions in France. Indeed DRDs are still occurring to a lesser 
extent, and with buprenorphine there is still the issue that the majority of these 
deaths are due to polydrug use.46,74–76,84,88 One further concern with increased 
buprenorphine use is its poor response to naloxone,74 therefore wider use may work 
against potential DRD reductions achieved through Scotland’s national naloxone 
programme. 
Other synergistic CNS depressant effects such as cognitive impairment, increased 
sedation, respiratory depression, etc., also occur when benzodiazepine-type drugs 
are used in combination with other opioids, tricyclic antidepressants (TCAs), 
antiepileptics, antipsychotics, sedating antihistamines and others, and will be further 
complicated by polydrug use.  
Clinical practice consideration 
 Review of current buprenorphine use in the context of significant DRD 
reductions in France. Would it be appropriate to increase buprenorphine 
use in specific opiate substitution cohorts?  
Clinical practice research considerations 
 Within Scotland what are the differences between buprenorphine and 
methadone DRDs with/without benzodiazepines? 
 How does this compare with ‘near-misses’ and are there cohort effects? 
 
Policy consideration 
 Review on the appropriateness of wider buprenorphine use in specific 
opiate substitution treatment cohorts. 
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Adverse effects 
Many of the benzodiazepine and z-hypnotic adverse effects are commonly known: 
sedation, cognitive impairment, amnesia and dependence,29 with higher doses being 
associated with more CNS depression65 and cognitive impairment, as seen with road 
traffic accidents92,93 and risk of falls in the elderly.94 More recently, studies have 
shown an association between benzodiazepine use and dementia. However, these 
studies do not show causation and acknowledge that benzodiazepine use may be 
associated with the treatment of prodromal dementia symptoms.95–98  
Cognitive impairment is of concern as it may affect substance users’ risk of ‘double 
dosing’ or taking multiple doses due to forgetfulness. Benzodiazepines are known to 
affect delayed recall (information presented minutes or hours earlier) rather than 
immediate recall (information presented seconds earlier). Different benzodiazepines 
have different amnesiac effects, such as short-acting drugs (lorazepam, 
flunitrazepam and triazolam) affecting recall more than longer-acting drugs 
(clonazepam, diazepam, oxazepam, etc.), although variations in dose may also 
influence amnesiac effects.68,99 These cognitive effects are associated with poorer 
psychotherapy outcomes in some conditions such as post-traumatic stress 
disorder,100 and may influence the outcomes in other anxiety disorders.101 However, 
variations in different psychotherapies, treatment engagement and adherence, and 
poorer motivation to changes in substance-use patterns may also contribute to 
poorer psychotherapy outcomes.100 Long-term benzodiazepine use is associated 
with significant cognitive impairment,102 and improvements in cognitive function are 
seen after benzodiazepine withdrawal. However, some individuals’ cognitive 
impairment may continue for years after withdrawal.27,103 Therefore, it may be more 
appropriate for substance users to minimise benzodiazepine use before engaging 
with psychosocial interventions to help optimise treatment outcomes. 
Less well-known effects, such as paradoxical and proarrhythmicm effects, may have 
significant effects in drug-related risks and DRDs. 
Paradoxical effects and decision making 
Paradoxical, also known as disinhibitory, effects of benzodiazepines, such as 
increased anxiety, insomnia, agitation, paranoid ideation, excessive tearfulness, 
inappropriate sexual behaviour, aggression and violence, are considered to be 
uncommon, affecting <1% of patients prescribed doses within the normal range. 
However, between 1% and 20% of those prescribed benzodiazepines may be 
affected,39 with higher doses, the use of short-acting drugs and/or comorbid mental 
                                                          
m An abnormality of cardiac rhythm such as a slow (bradycardia), fast (tachycardia) and/or 
irregular heart beat is a called a cardiac arrhythmia. Cardiac arrhythmias are caused by a 
defect in the generation or conduction of electrical impulses in the heart. Drugs which 
interfere with generation or conduction of electrical signals are commonly termed 
proarrhythmic. Drugs which are used to treat arrhythmias, such as digoxin, have 
antiarrhythmic properties; however, at high and toxic doses digoxin demonstrates 
proarrhythmic effects and can cause slow or fast heart rate.26 
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health problems – such as personality disorder – being associated with a higher 
incidence of paradoxical effects in susceptible individuals,39,104,105 especially those 
with poorer impulse control.106 In a small study (n=100), 55% of drug users reported 
disinhibitory violent and aggressive behaviour with temazepam use,8 where median 
temazepam and diazepam doses range from 40mg to 150mg10,44 as opposed to the 
maximum licensed daily doses of 40mg and 30mg, respectively.29 To a lesser extent, 
paradoxical effects including visual hallucinations, euphoria, disinhibition and 
agitation have been reported with z-hypnotics, especially zolpidem, at routine and 
higher doses.51,53,107–112 
Disinhibition associated with benzodiazepine-type drugs may be further intensified 
by benzodiazepine and/or z-hypnotic-induced cognitive impairment29 affecting 
substance users’ response to seek help when they observe or are experiencing an 
overdose. When alcohol is taken in combination with benzodiazepine-type drugs it 
can act synergistically, amplifying disinhibitory and dissociative behaviours.106,107 
Benzodiazepine-type drug use is also associated with suicidal thoughts and suicide 
attempts. With no evidence of causality, however, it is only one of the many factors 
which are associated with suicide in both the general and substance-using 
populations.107–109,113–115 Depression plays a more significant role, with around a 
quarter to a third of heroin users meeting the criteria for major depressive 
disorder,59,113,115 which benzodiazepine and/or z-hypnotic use is known to 
aggravate.68,110,116 Although benzodiazepine and methadone users report more 
deliberate overdoses than methadone-only users,117 it is hard to clarify if 
benzodiazepines increase suicidal behaviours in the substance-using populations, 
as it may just be one of the many contributing factors associated with a drug-using 
lifestyle which puts susceptible individuals at greater risk.59,115 
Clinical practice research considerations 
 Do substance users report difference in disinhibition with different 
benzodiazepine-type drugs and what dose relationship might there be? 
 Do disinhibitory effects affect user response to seek help and/or use 
naloxone? 
 What is the difference in benzo-burden between suicide and non-suicide 
DRDs? 
 How much of an improvement in depressive symptoms is achieved with 
managed withdrawal of benzodiazepine-type drugs in users stabilised on 
opiate substitution treatment?  
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Arrhythmic effects 
Diazepam has been shown at normal doses – 14mg intravenous (15mg orally) – to 
significantly shorten cardiac sinus cycle length and improve atrioventricular node 
conduction without significant effects in other cardiac tissues, which may present as 
proarrhythmic and antiarrhythmic effects in susceptible patients.118 At normal doses, 
diazepam and other benzodiazepines have been shown to reduce blood pressure 
and increase heart rate, which is only partially explained by reductions in blood 
pressure. However, autonomic neurocardiac regulation may be influenced first by 
reductions in central vagal tone and second by direct decreases in the cardiac 
pacemaker.119 This runs contrary to an older small study (n=10)41 which observed a 
weak correlation with blood concentrations of benzodiazepines and heart rate but did 
not correlate with ECG changes. However, 4 in 10 patients had also taken 
antipsychotics or TCAs, which are known to have arrhythmic effects.29 There have 
also been reports of phenazepam causing tachycardias and bradycardias in acute 
poisoning,43 but arrhythmias and cardiac toxicity are rarely reported with  
z-hypnotics.28 
The observed proarrhythmic effects with normal benzodiazepine doses need to be 
considered in the context of DRDs, substance use and treatment. Substance users 
tend to take much higher megadoses of 100mg to 150mg diazepam or 100mg 
zopiclone.10,51 A large proportion are also co-prescribed antipsychotics, 
antidepressants and/or methadone,120 which are known to cause QTcn prolongation 
with larger doses causing greater QTc prolongation.122,123 QTc prolongation is of 
concern as it is associated with ventricular tachycardia and sudden cardiac death 
which cannot be confirmed from autopsy findings.121 Older users with multimorbidity, 
such as cardiovascular disease or electrolyte imbalances associated with liver 
disease, and polydrug use are at greater risk of these adverse effects.5,124–126 
Clinical practice research considerations 
 Are there differences in QTc interval for substance users prescribed regular 
benzodiazepines and not prescribed regular benzodiazepines? 
 Is there a dose response relationship between QTc prolongation and 
regular low, medium, high and supratherapeutic megadose benzodiazepine 
use?  
 
  
                                                          
n The QT interval on an electrocardiogram describes the manifestation of ventricular 
depolarization and repolarisation. The QT interval is inﬂuenced by heart rate, therefore it 
should be measured for rate correction allowing the calculation of the corrected QT interval 
(QTc). Bazett’s formula is considered the gold standard for QTc calculation.121 
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Polydrug use and interactions  
The use of more than one psychoactive substance, known as polydrug use, is 
common among substance users.127 As already acknowledged, concomitant use of 
benzodiazepine-type drugs with other substances may be used to reduce adverse 
effects of other drugs such as insomnia and/or anxiety or to enhance the effects of 
opioids.44–46 Polydrug use further complicates and increases the risk of drug–drug 
and drug–disease interactions, increasing the risk of adverse drug effects. Polydrug 
use accounts for 13% of drug-related hospital admissions128 and 97% of DRDs have 
multiple drugs present in the body at death, with more than one drug implicated in 
68% of DRDs in Scotland.5  
Alcohol is commonly found in combination with benzodiazepines in DRDs and 
interacts synergistically to increase CNS depression. There may be some variation in 
effects between different benzodiazepines, as diazepam and chlordiazepoxide pose 
a smaller risk of death by poisoning than temazepam when given as a hypnotic to 
patients suffering from alcoholism.129 However, these patients may not have taken 
the larger doses associated with substance use which may negate the observed 
differences in toxicity. Among the z-hypnotics, zolpidem is more commonly reported 
as causing adverse effects and demonstrating greater toxicity in combination with 
alcohol and other drugs, although the fatal toxicity index is lower for z-hypnotics; 
zolpidem and zopiclone estimates of ~2 deaths per million versus ~7 for 
benzodiazepines and ~150 for barbiturates,28,130,131 and adverse media attention 
may have influenced adverse event reporting in some countries.107 
Methadone substitution programmes are associated with reductions in DRDs.132,133 
Historically, however, co-prescribing of benzodiazepines in such programmes was 
common and was found to be associated with an increased risk of DRD.75,120 
Addiction services have worked to reduce co-prescribing134 and co-prescribing of 
diazepam has been low but slowly rising in the DRD cohort, up from 13% in 2010 to 
21% in 2013.5 In part this may be due to diazepam being prescribed in preference to 
other benzodiazepines and/or z-hypnotics; diazepam being the drug of choice for 
managed benzodiazepine withdrawal29,33,34 and trends mimicking those within the 
general population (see Appendix 1). 
The combination of benzodiazepines and methadone use versus methadone-only 
use has also been shown to be associated with increased QTc prolongation.135,136 
So far such adverse effects have not been reported for z-hypnotics, which are 
prescribed at lower doses than benzodiazepines. Peles et al135 noted that those 
receiving benzodiazepines had significantly longer QTc prolongation but were also 
prescribed significantly higher methadone doses (129 ± 30mg/day vs. 104 ± 
38mg/day). Meanwhile Mijatovic et al136 indicated that there was a significant 
correlation between diazepam dose (mean dose 31±10mg) and QTc prolongation, 
without a similar correlation with the methadone dose (mean dose 45± 15mg). 
Increased QTc prolongation with combination use of benzodiazepine and methadone 
may also be due to a combination of effects: reduced clearance of one or both 
substrates through competition for CYP 3A4 resulting in increased levels, or changes 
in heart rate and cardiac pacing39,118,119 which may be further exacerbated by 
comorbidities or metabolic imbalances.121 Risk of sudden death, which is associated 
with QTc prolongation, is hard to quantify and qualify, with a recent Cochrane review 
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concluding it was not possible to draw any conclusions about the effectiveness  
of QTc screening strategies for preventing cardiac morbidity/mortality in  
methadone-treated substance users.137 To further complicate QTc issues, there is a 
lack of expert consensus on what constitutes prolongation and when to treat.138 
Where small to high doses of TCAs, such as amitriptyline, are added to 
benzodiazepine and methadone combinations it is expected that there will be further 
increases in cardiac toxicity risk and QTc prolongation, which are directly correlated 
with TCA dose.122,139 Blood drug concentrations would possibly also increase, as all 
three drugs are substrates for the CYP 3A4 pathway, in turn increasing synergistic 
effect such as CNS depression. Such a scenario could result in further cardiac 
toxicity and respiratory depression, which is associated with greater mortality 
rates.21,140,141 
CNS and respiratory depression is a synergistic pharmacodynamic effect associated 
with the use of other opioids such as heroin, morphine, oxycodone, buprenorphine 
and tramadol alongside benzodiazepine-type drugs. As already acknowledged 
above, in overdose situations competition for phase II (glucuronidation pathways) 
may reduce the clearance of drugs competing for the same pathway leading to 
higher blood concentrations and subsequently greater adverse effects.79 However, 
there is also at least one case report of lorazepam antagonising the effects of 
morphine.83 
Clinical practice research considerations 
 What are the differences in DRD subpopulations with and without 
benzodiazepine-type drugs present: 20–30% not present, 40–50% present 
and 20–30% implicated? 
 Where alcohol is present in combination with benzodiazepine-type drugs, is 
there an increase in proportion of female deaths due to lower capacity to 
metabolise alcohol than males? 
 What is the role of benzodiazepine-type drugs and polydrug combinations in 
fatalities and non-fatalities for drug-related hospital admissions? 
 Is there a dose response increase in QTc for methadone maintenance 
service users co-prescribed diazepam and methadone? 
o Fixed methadone dose with low (≤10mg/day), medium 
(>10mg≤20mg/day), high (>20mg≤30mg/day), very high (>30mg/day) 
diazepam dose. 
o Fixed methadone dose with low (≤10mg/day), medium 
(>10mg≤20mg/day), high (>20mg≤30mg/day), very high (>30mg/day) 
total benzo-burden as diazepam equivalents. 
o Are there gender, age and ethnicity differences between subgroups? 
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 Does QTc interval change for service users co-prescribed diazepam and 
fixed-dose methadone and diazepam managed reductions, diazepam 
starting dose >30mg/day. 
 Are there gender, age and ethnicity differences between subgroups? 
 What are the risks associated with co-prescribed drug combinations, such 
as methadone, TCAs and benzodiazepines?  
Toxicology 
When investigating potential DRD cases in Scotland, toxicology units routinely 
screen for: diazepam, nordiazepam (active metabolite), temazepam, oxazepam, 
lorazepam, chlordiazepoxide, nitrazepam and zolpidem. In Scotland, zolpidem and 
zopiclone account for 5% and 24%, respectively, of all benzodiazepine and  
z-hypnotics dispensed in primary care, with zopiclone prescribing continuing to 
increase as a proportion of all benzodiazepine-type drugs.13 In part this is due to 
zopiclone being prescribed in preference to temazepam which has significantly 
increased in cost. Due to the widespread use of zopiclone and substance users 
acknowledging its use, it would seem appropriate to include zopiclone in routine 
screening.10  
Due to z-hypnotics having a short half-life it has been suggested that in  
z-hypnotic-related deaths the maximum recommended time interval for detection is 
48 hours in blood and 72 hours in urine.30 However, due to the volume of DRDs and 
autopsies in the west of the country, some samples may be taken up to 7 days or 
more after death, therefore antemortem elimination may have already occurred. This 
will be especially problematic where zaleplon has contributed to DRDs due to its 
significantly shorter half-life and the very short sampling window allowing for blood 
analysis. Therefore, although zaleplon may potentially contribute to DRDs it will be 
very difficult to qualify and quantify its role.28 As benzodiazepine-type NPS use and 
presence in DRDs is increasing, it may also be appropriate for phenazepam and 
etizolam to be included in routine testing.5,12 
It is unclear what role blood concentrations play in the risk of benzodiazepine-related 
DRDs, as there are significant overlaps in fatal and non-fatal intoxications.41,81 This is 
also an issue for fatal and non-fatal methadone intoxications,142 complicating the 
certainty with which drugs are implicated in individual DRDs. However, polydrug use 
may be of more importance here, as the majority of benzodiazepine DRDs include 
other drugs.20 Higher morphine and methadone concentrations are seen in 
morphine-only and methadone-only DRD cases when compared with the polydrug 
cases with the same opioid,67,143 resulting in greater toxicity with combination 
use.21,25,46,76 
Discussions with Police Scotland identified a preference for toxicology data to be 
reported as a single national dataset, with one central point of contact at the end of 
each quarter. This would help to improve continuity, minimise error, and enable 
dataset mismatches to be identified and dealt with at one point in time. Toxicology 
indicated that the data is owned by the Procurator Fiscal and permission would need 
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to be agreed and granted for the data to be transferred as agreed within protocol. 
However, toxicology should not be used outwith the context of the case, to avoid 
coming to incorrect conclusions about the cause of death, e.g. a fall from height or 
major trauma causing a death which was not necessarily associated with drug levels. 
 
Police Scotland consideration 
 Toxicology reporting and data transfer to be discussed with Procurator 
Fiscal’s Office to consider and agree a single quarterly data transfers with 
single point of contacts between Police Scotland and Toxicology Services. 
 
Clinical practice research consideration 
 How does DRD cases benzo-burden and prescribing patterns compare with 
‘near miss’ cases of intentional and accidental drug poisonings admitted to 
hospital? 
Comorbidity 
The UK population is ageing with the proportion of over 65 years olds in Scotland 
projected to increase from 18% (0.95/5.33 million) in 2013 to 25% (1.47/5.78 million) 
in 2037.144 Moreover, the proportion of the population estimated to be problem drug 
users over 35 years old also increased from 42% in 2009/10 to 48% in 2012/13,145 
while the proportion of individuals over 40 years olds attending for an initial 
assessment at specialist drug treatment services increased from 15% in 2006/07 to 
26% in 2012/13.146 In addition, an English study also indicated that there was 
significant growth in older (50 to 74 years old) substance users and highlighted that 
these people were more likely have poorer health and die of non-DRD causes than 
DRDs when compared with younger substance users.126 
 
 
Toxicology practice and research considerations 
 Zopiclone to be included in routine screening with zolpidem. 
 Phenazepam and etizolam to be included in routine screening. 
 How do benzodiazepine-type drug patterns present in toxicology change 
with time? 
 Are there geographical hotspots in relation to benzodiazepine-type drugs 
being reported in DRDs and do these hotspots changing with time? 
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In the general population it is well known that morbidity and multimorbidity increases 
with age, with multimorbidity occurring 10–15 years earlier in people living in the 
most deprived areas.147 Multimorbidity is also associated with increased 
polypharmacy,o where patients are prescribed multiple drugs for multiple conditions 
on the advice of multiple specialists or in line with multiple clinical guidelines,147 
increasing the risk of avoidable adverse drug effects and hospital admissions.148,149 It 
is suspected that substance users in and out of treatment will be at higher risk of 
developing earlier multimorbidity and therefore receive multiple prescription 
medicines for these conditions which will further complicate drug–drug interactions 
and drug–disease interactions. An Italian study has also shown that benzodiazepine 
users (benzodiazepine only vs. methadone maintenance and benzodiazepines vs. 
methadone only) using the 12-item General Health Questionnaire rate their health as 
being much worse than methadone-only patients, who rate their health as being 
comparable to the general population.150 
As the majority of substance users smoke and are known to have reduced 
pulmonary function,124 we would expect there to be a greater prevalence of chronic 
obstructive pulmonary disease (COPD) in this population than in the general 
population. We would also expect older users to have more severe COPD, as with 
the general population, as they will have smoked for longer. However, previous 
studies have only captured asthma information or categorised all respiratory 
conditions in a single category.5,126,151 As benzodiazepine-type drug, and/or opioid, 
overdoses cause respiratory failure, and moderate/severe COPD can also cause 
respiratory failure, we would expect to see synergistic effects with both factors 
contributing to DRDs.152  
Liver disease may reduce benzodiazepine and z-hypnotic clearance, increasing the 
drug’s half-life and prolonging drug effects, with these varying with disease severity 
and drug used. For example, oxazepam’s clearance is less affected by hepatic 
failure at normal doses.41,79 It has also been reported that overweight patients’ 
greater liver size results in a greater quantity of enzymes, providing greater 
metabolic capacity.79 However, overweight patients have a greater risk of sleep 
apnoea, which is a known contra-indication for the use of benzodiazepines and  
z-hypnotics,29 with a recent study also highlighting the association between obesity 
(mean body mass index 39 kg/m2) and short-acting hypnotics.153 Conversely, 
underweight and/or malnourish users may be more susceptible to adverse drug 
effects and DRD due to lower hepatic capacity and reduced drug protein binding. 
Cardiovascular disease may also be associated with an increased risk of DRD, as 
some conditions – heart failure, cardiomyopathy, acute and chronic alcohol  
abuse – are more likely to be associated with arrhythmias.152  
Benzodiazepines-type drugs also play a conflicting role in relation to mental health. 
However, benzodiazepine-type drugs can be effective for alcohol and substance 
withdrawal; short-term management of anxiety;29–31,33,34 and are of marginal benefit 
for the short-term treatment of insomnia.154,155 Longer-term use is associated with 
                                                          
o The term polypharmacy just means ‘many medications’ and has often been defined as a 
patient taking five or more medications. 
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greater depressive symptoms68,110,116 and depression is known to be associated with 
greater substance user mortality.125,156 
Practice consideration 
 Future DRD and substance misuse databases should capture and code 
separate respiratory diseases: COPD, asthma, mixed asthma COPD and 
respiratory other. 
 
Clinical practice research considerations 
 Do a greater proportion of DRDs involving benzodiazepine-type drugs  
have COPD in comparison with benzodiazepine-type drug users who are 
‘near-miss' survivors?  
 Within the DRD cohort where benzodiazepine-type drugs are present, are 
there changes in the proportions of individuals with hepatic disease or 
cardiovascular disease when compared with the non-benzodiazepine-type 
drug cohort? 
 Are there associations between body mass index and benzodiazepine-type 
drugs in DRDs? 
 What impact does managed benzodiazepine-type reductions have on 
mental health such as depressive symptoms, cognition and coping skills, 
and substance use behaviours? 
 
Mortality and prescribed benzodiazepine-type 
drugs  
A recent large UK general practice population database study indicated that 
benzodiazepines and/or z-hypnotics drugs are associated with increased mortality 
hazards for adults.157 Within this study, attempts were made to adjust for 
confounding factors such as age, gender and comorbidities, but unfortunately it  
has been widely reported that common mental health problems which 
benzodiazepine-type drugs can be prescribed for are poorly coded in general 
practice, placing some of the findings in doubt.158–160 A recent US veterans study 
also indicated that there was an associated increased risk of overdose death for 
people co-prescribed benzodiazepines (z-hypnotics where excluded) and opioids, 
with the main factors being: co-prescription of benzodiazepines and opioids; longer 
duration of benzodiazepine prescription; and an increased risk of death with higher 
benzodiazepine doses prescribed.161 Unfortunately, this study used the long-acting 
drug clonazepam as their drug reference when comparing the risks between different 
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benzodiazepines, demonstrating that other drugs were safer.p Compared with UK 
benzodiazepine prescribing there was a larger proportion of people in wealthier 
areas receiving benzodiazepines.162 However, other studies present a more mixed 
picture, with benzodiazepine-type drugs being associated with varying mortality 
hazards in different populations: increased mortality hazards in middle-aged 
populations and substance misuse populations, but not in elderly 
populations.120,163,164  
The use of benzodiazepine-type drugs has been associated with a significantly 
greater risk of developing pneumonia and dying from pneumonia, with some drugs 
having greater risks than others (Table 3).165 Chlordiazepoxide was not associated 
with increased pneumonia incidence, possibly due to its short,term use for alcohol 
withdrawals, and lorazepam was associated with increased hazard ratio for 30-day 
mortality, which may reflect its greater use in care home populations.166 The 
association between benzodiazepine-type drug use and pneumonia may play a 
significant role for immunocompromised substance users and those experiencing 
DRD near misses with accidental overdoses.  
Clinical practice and pathology consideration 
 What are the proportion of non-fatal benzodiazepine-type drug overdoses 
that subsequently die of pneumonia?  
 
 
 
 
 
                                                          
p Using alprazolam as a reference may have been more appropriate, as it demonstrates 
greater toxicity than other benzodiazepines in overdose.65 
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Table 3 Benzodiazepine-type drugs associated with the occurrence of pneumonia and mortality from pneumonia 
Drug Association between exposure and 
pneumonia incidence 
Association between 30-day and long-term mortality 
*Adjusted OR (95% CI), p-value 30-day 
*HR adjusted (CI 95%),  
p-value 
Long-term 
*HR adjusted (CI 95%),  
p-value 
Benzodiazepine 1.54 (1.42 to 1.67), p<0.001 1.22 (1.06 to 1.39), p=0.004 1.32 (1.19 to 1.47), p<0.001 
Diazepam 1.49 (1.34 to 1.65), p<0.001 1.24 (1.04 to 1.47), p=0.014 1.27 (1.11 to 1.46), p=0.001 
Lorazepam 1.65 (1.24 to 2.20), p=0.001 1.61 (1.14 to 2.28), p=0.007 1.48 (1.10 to 2.00), p=0.010 
Chlordiazepoxide 1.19 (0.88 to 1.62), p=0.248 1.58 (0.98 to 2.57), p=0.063 1.49 (1.02 to 2.17), p=0.038 
Temazepam 1.43 (1.29 to 1.59), p<0.001 1.11 (0.95 to 1.29), p=0.208 1.20 (1.06 to 1.36), p=0.003 
Zopiclone 1.98 (1.49 to 2.64), p<0.001 0.93 (0.55 to 1.53), p=0.738 1.11 (0.77 to 1.60), p<0.564 
Adapted from Obiora et al.165 
*Adjusted for age, sex, Townsend deprivation score, smoking status, Charlson comorbidity index score, alcohol use, depression and psychosis. 
HR: hazards ratio; OR: odds ratio
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Acute pharmacological treatment of overdose 
Non-fatal overdoses are observed among a large proportion of substance users.59,167 
Among fatal overdoses in Scotland, it is also well documented that ambulances are 
consistently called to more than 80% of cases recorded as DRDs.5 Among the cases 
where an ambulance did not attend, there were 4% when an ambulance was not 
required because it was clear that the deceased was beyond medical intervention.5 
The greater use of antidotes such as naloxone by substance users, associates and 
family may have a positive impact on reducing DRDs.168  
Flumazenil, a short-acting benzodiazepine antagonist, is widely available in the UK 
but not licensed for use in overdose. This is possibly because flumazenil use in 
overdose can be hazardous, particularly in mixed overdoses involving tricyclic 
antidepressants or in benzodiazepine-dependent patients, and requires the 
correction of respiratory, cardiac and metabolic conditions before administration.29,169 
Flumazenil also needs to be administered intravenously, which may be impractical 
for emergency use as intravenous access is not always possible in some substance 
users. Despite this, some non-UK ambulance services have reportedly used 
flumazenil in a minority of patients.170 UK ambulance service guidance does not 
advocate this, due to the significant risks associated with destabilising patients.171,172 
A French survey of accident and emergency flumazenil use considered it to be 
dangerous and/or contraindicated in 38% of patients who received it due to patients 
being chronic benzodiazepine users, taking benzodiazepines in combination with 
TCAs or experiencing convulsions or cardiac arrhythmias, and estimated a 12% 
prevalence of potentially harmful use of flumazenil.173 However, a more recent UK 
study indicated that where flumazenil was used to treat benzodiazepine overdose 
there was a low incidence of seizures.174 Although flumazenil can be effective in 
reversing benzodiazepine and z-hypnotic effects,29,175–177 as the majority of DRDs 
and a large proportion of drug-related hospital admissions in Scotland are due to 
polydrug overdoses the widespread use flumazenil would also appear to be 
inappropriate.5,128 
Unexpectedly, naloxone – a short-acting opioid antagonist which can be 
administered by intravenous or intramuscular injection – has been used with mixed 
success to reverse benzodiazepine and z-hypnotic effects,176–185 reversing overdose 
toxicity in benzodiazepine-only cases178 and mixed benzodiazepine and non-opiate 
cases.179,180 Studies demonstrating a lack of effect did not include benzodiazepine 
overdoses (Table 4).184–186 Interestingly, the studies demonstrating a lack of effect 
use benzodiazepine doses at half to less than a tenth of the doses seen in overdose, 
and assessed naloxone response within 10 minutes post administration where on 
average it took 12 minutes (ranging from 5 to 20 minutes) for patients to respond.179  
Although naloxone is known to be a specific opioid antagonist that acts competitively 
with opioids at opioid receptors, there is some evidence that it also possibly 
antagonises GABA/benzodiazepine receptor function.187 However, further research 
is required to confirm or refute previous studies and clarify naloxone’s mechanism of 
action in benzodiazepine overdose, although as already acknowledged the majority 
of overdoses are for polydrug use where opiates are also present.5,128  
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Clinical practice research consideration 
 Is there a role for naloxone in acute benzodiazepine-type drug overdose? 
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Table 4 Studies involving naloxone to treat benzodiazepine-type drug intoxication 
Study Study 
design 
Population Drugs BDZ and mean diazepam 
equivalent (mg) 
Naloxone 
dose 
Comment 
Positive studies 
Sohli et al178 Randomised 
controlled 
Overdose, 
n=116 
28 ± 11 years 
old, 63% 
female. 
BDZ only Diazepam  149mg po 0.8mg iv Improvement in Glasgow 
Coma Scale for all 
patients, although 
lorazepam group was 
not statistically 
significant (p=0.24) 
Clonazepam 320mg po 
Alprazolam  180mg po 
Lorazepam  230mg po 
Malizia et 
al179 
Observational Overdose, 
n=10 
Mean 19.6 
years old, 
range 18 to 
30 years.  
7 BDZ only 
3 BDZ + other  
(1 cranial 
trauma,  
1 barbiturate + 
alcohol,  
1 amitriptyline 
+ alcohol†) 
Not stated 0.8mg to 
2.0mg iv 
Time taken to waken 5 to 
20 minutes, mean 11.7 ± 
4.6 minutes. Respiration 
increased from 8 to 15 
breaths per minute within 
10–15 minutes of 
naloxone 
Jordan et 
al181 
Double-blind 
crossover 
Healthy 
males, 25–45 
years old, 
n=6 
BDZ only Diazepam 15mg/70kg iv Placebo 
(saline) or 
naloxone 
15mg/70kg 
at 60 
minutes and 
95 minutes. 
Improvement in 
respiration over 3 hours 
at significantly (p<0.05) 
quicker rate than 
placebo 
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Study Study 
design 
Population Drugs BDZ and mean diazepam 
equivalent (mg) 
Naloxone 
dose 
Comment 
Stella et 
al182 
Double-blind 
randomised 
control 
Adults, 20–50 
years old, 
n=136 
Elective 
abdominal 
surgery. 
Mixed 
anaesthetics 
Diazepam 0.345mg/kg (20mg 
to 27mg) 
Thiorpentone 2.188mg/kg 
Alphaxolone 0.273mg/kg 
Propanidid 1.747mg/kg 
Ketamine 0.404mg/kg 
Placebo 
(saline) or 
naloxone 
0.3mg to 
0.5mg iv,  
5 minutes 
before 
induction 
Significant reduction in 
unconsciousness in 
diazepam group 
receiving naloxone 
Moss180 Case Overdose, 
46-year-old 
female. 
Mix: 
diazepam, 
talbutal and 
alcohol. 
Diazepam 75mg po 
Talbutal 120mg po 
0.4mg iv No narcotics where 
detected in blood 
samples. 
Negative studies 
Christensen 
and 
Huttel186 
Double-blind 
randomised 
control 
Adults, n=46 
Gastroscopy 
BDZ only Diazepam 33.5mg  
(20–50mg), n=22 
Diazepam 35.5mg  
(20–60mg), n=24 
Placebo 
(saline) vs. 
0.4mg iv 
Glasgow Coma Scale  
5 min before and after 
administration, 
conscious level was not 
significantly different 
between groups (p=0.02) 
Wolkowitz 
et al184 
Double-blind 
placebo 
crossover 
study 
Males, 18–21 
years, n=10 
BDZ only Diazepam 0.25mg/kg 
(17.5mg/70kg) or placebo 
1.2mg iv Diazepam produced 
marked reduction in 
measures of cognitive 
functioning. Naloxone 
had no effect on 
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Study Study 
design 
Population Drugs BDZ and mean diazepam 
equivalent (mg) 
Naloxone 
dose 
Comment 
cognitive functioning 
measures. 
Forster et 
al185 
Randomised 
double-blind 
crossover 
Healthy 
males, mean 
age 30 ±  
4 years, n=8 
BDZ only Midazolam iv Diazepam po Placebo 
(saline) or 
naloxone 
0.015mg/kg 
(1mg) iv 
after 5 
minutes 
Study period 10minutes.  
Respiratory effects of 
midazolam are poorly 
dose related and not 
reversed by naloxone 
Placebo Nil 
0.05mg/kg 9mg 
0.1mg/kg 18mg 
0.2mg/kg 35mg 
Lheureux et 
al176 
Case  Overdose: 
50-year-old 
male,  
Prothipendyl 
and alcohol 
Zolpidem 300mg 
(~150mg diazepam) 
1mg 
naloxone iv 
No improvement 
consciousness or 
respiratory symptoms. 
Cienki and 
Burkhart177 
Case Overdose: 
27-year-old 
male 
Possible 
mixed 
flunazerine 
Zopiclone 105mg to 150mg 
(~70mg to 100mg diazepam) 
2mg 
naloxone iv 
No effect 
BDZ: benzodiazepine; po: orally; iv: intravenous. 
† patient died after 60 hours, cause of death attributed to aspiration pneumonia. 
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Conclusion 
The role of benzodiazepine-type drugs in DRDs is complicated by numerous factors 
including: increasing availability of unregulated benzodiazepine-type NPS of 
unknown content and quality; self-medicating with prescribed and/or illicit 
benzodiazepine-type drugs; the use of supratherapeutic megadoses and the lack of 
information about the metabolic and physical effects of such doses; polydrug use 
and polypharmacy further complicating adverse drug effects; low and high drug 
blood concentrations being present in DRDs; benzodiazepine-type drugs being 
associated with increased mortality when used at routine doses; and the real risks of 
short-term and long-term mental health and cognitive problems associated with 
routine and excessive benzodiazepine-type drug use.  
However, in assessing the risks posed by benzodiazepine-type drugs, one must 
consider the risks of the alternatives. Therefore, a better understanding of 
benzodiazepine-type drug use may enable the development of appropriate strategies 
to reduce and minimise drug-related harms, and to replicate previous achievements 
associated with the withdrawal of temazepam capsules.  
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Glossary 
Term Definition 
ADE Adverse drug effect 
Agonist 
Drug which attaches to a receptor producing the same 
effect to the body's natural molecule  
Antagonist 
Drug which attaches to a receptor interfering with or 
preventing the body's natural agonist effect  
Benzo-burden 
Benzodiazepine-type drug use includes dose, drug 
potency, frequency of use, exposure, etc. 
Benzos Benzodiazepine-type drugs 
Blues Blue diazepam (valium) 10mg tablets 
CNS Central nervous system 
DDD Defined daily doses 
DDD/1000 
population 
Defined daily doses per 1000 population. Using mid-year 
population estimates from General Registrar’s Office for 
Scotland 
Drug half-life 
The time taken for drug blood concentrations to reduce by 
50% 
GABA Gamma-aminobutyric acid – an inhibitory neurotransmitter 
Items Prescriptions 
Megadose Large dose outwith the licensed dose 
NPS  New or Novel Psychoactive Substance 
Paradoxical effects Effects similar to those the drugs are being used to treat 
Pharmacodynamics 
Study of how the effects of drugs are enhanced or 
diminished in the presence of other drugs 
Pharmacokinetics 
Study of how drugs are absorbed into, distributed, broken 
down in and excreted from the body 
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Term Definition 
Polydrug 
Multiple drug; commonly used to described multiple drug 
use 
Polypharmacy Multiple prescribed drug use 
QTc 
QT interval corrected. Prolonged QTc increases the risk 
of sudden cardiac death from heart arrhythmias, such as 
ventricular tachycardias  
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Appendix 1 – Anxiolytic and hypnotic 
prescribing data Scotland 
Figures developed from Information Services Division Scotland prescribing data.q13 
 
                                                          
q World Health Organisation DDDs are defined as ‘the assumed average maintenance dose 
per day for a drug used for its main indication in adults’ and do not necessarily reflect the 
recommended or prescribed daily dose. Instead they provide a standardised method to 
compare prescribing volumes between organisations.35 
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Figure 2 Anxiolytic and hypnotic DDDs per 1000 population per day by 
Scottish Health Board.
Greater Glasgow & Clyde Lanarkshire Western Isles Fife
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Note: prescription (items) numbers diverging from DDDs/1000 population per day indicates 
that prescribers are issuing smaller quantities of anxiolytics and hypnotics on individual 
prescriptions, e.g. 28-day prescriptions instead of 56-day prescriptions, 28 day prescription 
with 28 tablets instead of 56 tablets. 
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Figure 3 Anxiolytic and hypnotic prescriptions (items) and DDDs per 1000 
population per day by financial year for Scotland.
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Note: Diazepam accounts for the majority of anxiolytics prescribed, but it is also used for 
benzodiazepine and z-hypnotic withdrawal, which will partially account for the observed 
increase in anxiolytic DDDs/1000 population per day. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
2
4
6
8
10
12
14
16
0.0
0.2
0.4
0.6
0.8
1.0
1.2
D
D
D
/1
0
0
0
 p
o
p
u
la
ti
o
n
 p
e
r 
d
a
y
 
It
e
m
s
 (
m
ill
io
n
)
Financial year
Figure 5 Anxiolytic prescriptions (items) and DDDs per 1000 population per 
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Figure 6 Proportion of drugs prescribed by benzodiazepine and z-hypnotic DDDs, by financial 
year for Scotland
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Appendix 2 – Literature search strategy 
Benzodiazepines: Medline 1970 to March 2015 
# Search Actions 
Search 
type 
1 alprazolam.mp. or exp Alprazolam/ 2214 Advanced 
2 bromazepam.mp. or exp Bromazepam/ 501 Advanced 
3 brotizolam.mp. 196 Advanced 
4 chlordiazepoxide.mp. or exp Chlordiazepoxide/ 4507 Advanced 
5 clobazam.mp. 672 Advanced 
6 clonazepam.mp. or exp Clonazepam/ 3680 Advanced 
7 Clorazepate Dipotassium/ or clorazepate.mp. 447 Advanced 
8 cloxazolam.mp. 33 Advanced 
9 delorazepam.mp. 16 Advanced 
10 exp Diazepam/ or diazepam.mp. 23355 Advanced 
11 estazolam.mp. or exp Estazolam/ 161 Advanced 
12 etizolam.mp. 76 Advanced 
13 flunitrazepam.mp. or exp Flunitrazepam/ 3565 Advanced 
14 flurazepam.mp. or exp Flurazepam/ 1126 Advanced 
15 halazepam.mp. 57 Advanced 
16 ketazolam.mp. 34 Advanced 
17 loprazolam.mp. 71 Advanced 
18 lorazepam.mp. or exp Lorazepam/ 3748 Advanced 
19 lormetazepam.mp. 233 Advanced 
20 medazepam.mp. or exp Medazepam/ 243 Advanced 
21 nitrazepam.mp. or exp Nitrazepam/ 1186 Advanced 
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22 nordazepam.mp. or exp Nordazepam/ 496 Advanced 
23 midazolam.mp. or exp Midazolam/ 10626 Advanced 
24 oxazolam.mp. 28 Advanced 
25 oxazepam.mp. or exp Oxazepam/ 1717 Advanced 
26 phenazepam.mp. 290 Advanced 
27 pinazepam.mp. 36 Advanced 
28 prazepam.mp. or exp Prazepam/ 208 Advanced 
29 quazepam.mp. 142 Advanced 
30 temazepam.mp. or exp Temazepam/ 961 Advanced 
31 tofisopam.mp. 107 Advanced 
32 triazolam.mp. or exp Triazolam/ 1624 Advanced 
33 zolazepam.mp. or exp Zolazepam/ 318 Advanced 
34 
exp Benzodiazepines/ or exp Benzodiazepinones/ or 
benzodiazepin$.mp. 68636 Advanced 
35 hypnotic$.mp. or exp "Hypnotics and Sedatives"/ 110483 Advanced 
36 anxiolytic$.mp. or exp Anti-Anxiety Agents/ 61828 Advanced 
37 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 
33 or 34 or 35 or 36 167647 Advanced 
38 exp Mortality/ or exp Mortality, Premature/ or mortality.mp. 643133 Advanced 
39 
exp Death/ or death$.mp. or exp Death, Sudden/ or exp 
"Cause of Death"/ 646334 Advanced 
40 poisoning$.mp. or exp Poisoning/ 159772 Advanced 
41 drug related death$.mp. 490 Advanced 
42 drug associated death$.mp. 13 Advanced 
43 drug related mortality.mp. 78 Advanced 
44 drug associated mortality.mp. 1 Advanced 
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45 benzodiazepine related death$.mp. 1 Advanced 
46 benzodiazepine associated death$.mp. 0 Advanced 
47 benzodiazepine related mortality.mp. 1 Advanced 
48 benzodiazepine associated mortality.mp. 0 Advanced 
49 
38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 
48 1272296 Advanced 
50 adult.mp. or exp Adult/ 5988891 Advanced 
51 elderly.mp. or exp Aged/ 2427405 Advanced 
52 exp "Aged, 80 and over"/ or older people.mp. 649251 Advanced 
53 50 or 51 or 52 6009070 Advanced 
54 37 and 49 and 53 4869 Advanced 
55 
limit 54 to (english language and humans and yr="1970 -
Current") 3681 Advanced 
56 
exp Child, Preschool/ or exp Infant, Newborn/ or exp Child/ 
or paediatric$.mp. or exp Infant/ 2047455 Advanced 
57 55 not 56 3272 Advanced 
58 
exp Epilepsy, Generalized/ or exp Epilepsy, Temporal 
Lobe/ or exp Epilepsy, Benign Neonatal/ or exp Epilepsy, 
Partial, Motor/ or exp Epilepsy, Post-Traumatic/ or exp 
Epilepsy, Reflex/ or exp Epilepsy, Tonic-Clonic/ or 
epilepsy.mp. or exp Epilepsy, Partial, Sensory/ or exp 
Epilepsy, Absence/ or exp Epilepsy, Complex Partial/ or 
exp Epilepsy/ or exp Epilepsy, Rolandic/ or exp Myoclonic 
Epilepsy, Juvenile/ or exp Epilepsy, Frontal Lobe/ 142472 Advanced 
59 epileptic.mp. 28245 Advanced 
60 Seizures/ 42214 Advanced 
61 exp Electroconvulsive Therapy/ or ect.mp. 11196 Advanced 
62 exp Alcohol Withdrawal Delirium/ or alcohol withdrawal.mp. 3748 Advanced 
63 exp Alcohol Withdrawal Delirium/ or alcohol withdrawal.mp. 3748 Advanced 
64 
exp Neuroleptic Malignant Syndrome/ or exp Serotonin 
Syndrome/ or acute serotonin syndrome.mp. 2454 Advanced 
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Benzodiazepines: Embase 1970 to March 2015. 
# Search Results 
Search 
type 
1 alprazolam.mp. or exp alprazolam/ 15878 Advanced 
2 bromazepam.mp. or exp bromazepam/ 3136 Advanced 
3 exp chlordiazepoxide/ or chlordiazepoxide.mp. 12228 Advanced 
4 clobazam.mp. or exp clobazam/ 5214 Advanced 
5 clonazepam.mp. or exp clonazepam/ 21387 Advanced 
6 
exp clorazepate dipotassium/ or clorazepate.mp. or exp 
clorazepate/ or exp clorazepate potassium/ 
3836 Advanced 
7 cloxazolam.mp. or exp cloxazolam/ 235 Advanced 
8 delorazepam.mp. or exp delorazepam/ 360 Advanced 
9 diazepam.mp. or exp diazepam/ 69908 Advanced 
65 palliative care.mp. or exp Palliative Care/ 44486 Advanced 
66 terminal care.mp. or exp Terminal Care/ 41871 Advanced 
67 mechanical ventilation.mp. or exp Respiration, Artificial/ 71729 Advanced 
68 critical care.mp. or exp Critical Care/ 52786 Advanced 
69 
perioperative.mp. or exp Perioperative Care/ or exp 
Perioperative Period/ 212845 Advanced 
70 premedication.mp. or exp Premedication/ 26080 Advanced 
71 
exp Postoperative Care/ or exp Postoperative Period/ or 
postoperative.mp. 575519 Advanced 
72 
58 or 59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 
68 or 69 or 70 or 71 1009043 Advanced 
73 57 not 72 2278 Advanced 
74 from 73 keep 4, 6, 19, 21-22, 43, 46-47... 255 Advanced 
75 from 74 keep 1-2, 4-6, 9, 11, 14-15, 18-26... 164 Advanced 
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# Search Results 
Search 
type 
10 brotizolam.mp. or exp brotizolam/ 846 Advanced 
11 estazolam.mp. or exp estazolam/ 1093 Advanced 
12 etizolam.mp. or exp etizolam/ 387 Advanced 
13 flunitrazepam.mp. or exp flunitrazepam/ 8597 Advanced 
14 flurazepam.mp. or exp flurazepam/ 4714 Advanced 
15 halazepam.mp. or exp halazepam/ 356 Advanced 
16 ketazolam.mp. or exp ketazolam/ 322 Advanced 
17 
loprazolam.mp. or exp loprazolam mesilate/ or exp 
loprazolam/ 
382 Advanced 
18 lorazepam.mp. or exp lorazepam/ 21932 Advanced 
19 lormetazepam.mp. or exp lormetazepam/ 1356 Advanced 
20 medazepam.mp. or exp medazepam/ 1304 Advanced 
21 nitrazepam.mp. or exp nitrazepam/ 6432 Advanced 
22 nordazepam,.mp. or exp nordazepam/ 2085 Advanced 
23 
exp midazolam maleate/ or exp midazolam/ or 
midazolam.mp. 
36299 Advanced 
24 oxazolam.mp. or exp oxazolam/ 178 Advanced 
25 oxazepam.mp. or exp oxazepam/ 7837 Advanced 
26 phenazepam.mp. or exp phenazepam/ 462 Advanced 
27 pinazepam.mp. or exp pinazepam/ 117 Advanced 
28 prazepam.mp. or exp prazepam/ 1371 Advanced 
29 quazepam.mp. or exp quazepam/ 635 Advanced 
30 temazepam.mp. or exp temazepam/ 5284 Advanced 
31 tofisopam.mp. or exp tofisopam/ 343 Advanced 
32 triazolam.mp. or exp triazolam/ 5707 Advanced 
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# Search Results 
Search 
type 
33 exp zolazepam/ or zolazepam.mp. 463 Advanced 
34 
exp benzodiazepine derivative/ or benzodiazepine.mp. or 
exp benzodiazepine/ 
163842 Advanced 
35 anxiolytic$.mp. or exp anxiolytic agent/ 169107 Advanced 
36 hypnotic$.mp. or exp hypnotic agent/ 29941 Advanced 
37 
1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 
13 or 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 
23 or 24 or 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 
33 or 34 or 35 or 36 
262239 Advanced 
38 mortality/ 558573 Advanced 
39 mortality cause.mp. or exp "cause of death"/ 75926 Advanced 
40 death$.mp. or exp death/ 1031011 Advanced 
41 poisoning.mp. or exp intoxication/ 355270 Advanced 
42 overdose.mp. 27147 Advanced 
43 
exp drug fatality/ or drug related death$.mp. or exp drug 
intoxication/ 
37887 Advanced 
44 exp drug overdose/ or drug associated death$.mp. 17603 Advanced 
45 drug related mortality.mp. 113 Advanced 
46 drug associated mortality.mp. 2 Advanced 
47 benzodiazepine related death$.mp. 0 Advanced 
48 benzodiazepine associated death$.mp. 0 Advanced 
49 benzodiazepine related mortality.mp. 2 Advanced 
50 benzodiazepine associated mortality.mp. 0 Advanced 
51 
38 or 39 or 40 or 41 or 42 or 43 or 44 or 45 or 46 or 47 or 
48 or 49 or 50 
1767881 Advanced 
52 37 and 51 34297 Advanced 
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# Search Results 
Search 
type 
53 
limit 52 to (human and english language and yr="1970 -
Current") 
23182 Advanced 
54 child/ 1344716 Advanced 
55 newborn/ 482833 Advanced 
56 infant/ 530419 Advanced 
57 54 or 55 or 56 1938660 Advanced 
58 53 not 57 21104 Advanced 
59 exp epilepsy/ 182457 Advanced 
60 epileptic$.mp. 68408 Advanced 
61 seizure$.mp. or exp withdrawal seizure/ or exp seizure/ 174908 Advanced 
62 
seizure$.mp. or exp withdrawal seizure/ or exp seizure/ or 
exp "seizure, epilepsy and convulsion"/ 
300234 Advanced 
63 ect.mp. or exp electroconvulsive therapy/ 19085 Advanced 
64 alcohol withdrawal.mp. or exp alcohol withdrawal/ 7141 Advanced 
65 alcohol withdrawal delerium.mp. 0 Advanced 
66 palliative care.mp. or exp palliative therapy/ 74385 Advanced 
67 terminal care.mp. or exp terminal care/ 49478 Advanced 
68 intensive care.mp. or exp intensive care/ 566773 Advanced 
69 exp artificial ventilation/ 130740 Advanced 
70 cpap.mp. or exp positive end expiratory pressure/ 37451 Advanced 
71 
exp surgery/ or exp perioperative period/ or 
perioperative.mp. 
3587176 Advanced 
72 
59 or 60 or 61 or 62 or 63 or 64 or 65 or 66 or 67 or 68 or 
69 or 70 or 71 
4352732 Advanced 
73 58 not 72 10408 Advanced 
74 antipsychotic$.mp. or exp neuroleptic agent/ 237145 Advanced 
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# Search Results 
Search 
type 
75 premedication.mp. or exp premedication/ 68826 Advanced 
76 barbiturate$.mp. or exp barbituric acid derivative/ 137478 Advanced 
77 exp organic solvent/ or exp solvent/ or solvent$.mp. 462779 Advanced 
78 glycol$.mp. or exp glycol/ 145281 Advanced 
79 
exp anesthesia induction/ or exp propofol infusion 
syndrome/ or exp anesthesia/ or exp propofol/ or exp 
intravenous anesthesia/ 
293201 Advanced 
80 exp isoflurane/ or exp anesthesia/ or exp halothane/ 296323 Advanced 
81 exp pregabalin/ 8181 Advanced 
82 exp gabapentin enacarbil/ or exp gabapentin/ 21744 Advanced 
83 exp sclerosis/ 29533 Advanced 
84 exp rheumatology/ 44160 Advanced 
85 exp autoimmune disease/ or autoimmune.mp. 513354 Advanced 
86 cancer.mp. or exp neoplasm/ 3812832 Advanced 
87 
74 or 75 or 76 or 77 or 78 or 79 or 80 or 81 or 82 or 83 or 
84 or 85 or 86 
5439874 Advanced 
88 73 not 87 4680 Advanced 
89 from 88 keep 14, 22, 40, 42, 50, 55-57... 477 Advanced 
90 from 89 keep 1, 3-9, 11-19, 21, 23-24, 26-27... 273 Advanced 
Z-hypnotic: Medline 1970 to March 2015 
# Search Results 
Search 
type 
1 zopiclone.mp. 853 Advanced 
2 zolpidem.mp. 1816 Advanced 
3 zaleplon.mp. 300 Advanced 
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# Search Results 
Search 
type 
4 zaleplone.mp. 6 Advanced 
5 1 or 2 or 3 or 4 2505 Advanced 
6 exp Mortality/ or mortality.mp. or exp Mortality, Premature/ 656531 Advanced 
7 
exp Death/ or exp "Cause of Death"/ or death$.mp. or exp 
Death, Sudden/ 
658216 Advanced 
8 exp Poisoning/ or poisoning$.mp. 161322 Advanced 
9 drug related death$.mp. 495 Advanced 
10 drug associated death$.mp. 13 Advanced 
11 drug related mortality.mp. 79 Advanced 
12 drug associated mortality.mp. 1 Advanced 
13 z-hypnotic associated death$.mp. 0 Advanced 
14 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 1295832 Advanced 
15 5 and 14 121 Advanced 
16 
limit 15 to (english language and humans and yr="1970 -
Current") 
91 Advanced 
17 
exp Infant, Newborn/ or exp Child, Preschool/ or exp Child/ 
or paediatric$.mp. 
1949313 Advanced 
18 16 not 17 83 Advanced 
19 from 18 keep 1-3, 6-9, 12-13, 20, 22, 25-26... 43 Advanced 
Z-hypnotic: Embase 1970 to March 2015 
# Search Results 
Search 
type 
1 exp zopiclone/ 3368 Advanced 
2 exp zolpidem tartrate/ or exp zolpidem/ 6758 Advanced 
3 zalpelon.mp. 2 Advanced 
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# Search Results 
Search 
type 
4 exp zaleplon/ 1553 Advanced 
5 zaleplone.mp. 11 Advanced 
6 z-hypnotic$.mp. 41 Advanced 
7 1 or 2 or 3 or 4 or 5 or 6 9080 Advanced 
8 exp mortality/ 765640 Advanced 
9 mortality cause.mp. or exp "cause of death"/ 82212 Advanced 
10 death$.mp. or exp death/ 1121553 Advanced 
11 poisoning$.mp. or exp intoxication/ 390528 Advanced 
12 overdose.mp. 28141 Advanced 
13 
exp drug fatality/ or drug related death$.mp. or exp 
drug intoxication/ 
39372 Advanced 
14 drug associated death$.mp. 16 Advanced 
15 drug related mortality.mp. 120 Advanced 
16 drug associated mortality.mp. 3 Advanced 
17 z-hypnotic associated death$.mp. 0 Advanced 
18 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 2024565 Advanced 
19 7 and 18 1251 Advanced 
20 
limit 19 to (human and english language and yr="1970 
-Current") 
1050 Advanced 
21 child/ 1483162 Advanced 
22 newborn/ 518213 Advanced 
23 infant/ 576234 Advanced 
24 21 or 22 or 23 2125845 Advanced 
25 20 not 24 1011 Advanced 
26 from 25 keep 7, 11, 15, 36-39, 53, 56... 181 Advanced 
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# Search Results 
Search 
type 
27 from 26 keep 7, 15, 36-37, 40, 53... 146 Advanced 
 

